B4GALNT1 and urothelial carcinoma: In the Cancer Genome Atlas Urothelial Carcinoma (TCGA-BLCA) cohort [31], high levels of B4GALNT1 (beta-1,4-N-acetyl-galactosaminyltransferase 1) expression have been strongly linked to advanced clinical stages and poor prognosis [32].